☆ 4.7 Article

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

期刊

JOURNAL OF HEMATOLOGY & ONCOLOGY

卷 10, 期 -, 页码 -

出版社

BIOMED CENTRAL LTD

DOI: 10.1186/s13045-017-0414-2

关键词

RUNX1-RUNX1T1 transcript levels; Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Relapse; Donor lymphocyte infusion

类别

Oncology Hematology

资金

Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621001]
National Nature Science Foundation of China [81570130, 81530046]
Beijing Municipal Science and Technology Program [Z141100000214011]

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

摘要

Background: The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t(8;21) acute myeloid leukemia (AML). Methods: RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation (1530 samples in total). Results: A total of 92.3% of the requested samples were collected, and 74.0% of patients had complete sample collection. The 1-, 3-, and 6-month RUNX1-RUNX1T1 transcript levels could significantly discriminate between continuous complete remission and a hematologic relapse at 1.5-3, 4-6, and 7-12 months but not at >3, >6, and >12 months, respectively. Over 90% of the 175 patients who were in continuous complete remission had a >= 3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a >= 4-log reduction at >= 12 months. A <3-log reduction within 12 months and/or a <4-log reduction at >= 12 months was significantly related to a higher 3-year cumulative incidence of relapse (CIR) rate in both the entire cohort and the patients with no intervention after HSCT (58.4 vs. 2.2%, 76.5 vs. 2.0%; all P < 0.0001). Patients who had received a preemptive donor lymphocyte infusion when the increase in RUNX1-RUNX1T1 transcripts was <= 1-log according to the above dual cutoff values had significantly lower 1-year CIR rate after intervention than the patients who had received an infusion when the increase was >1-log (0 vs. 55.0%, P = 0.015). Conclusions: RUNX1-RUNX1T1 transcripts with a <3-log reduction from diagnosis within 12 months and/or a <4-log reduction at = 12 months after allo-HSCT could accurately predict relapse and may prompt a timely intervention in patients with t(8;21) AML.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.7

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation

Peng Zhao, Ming Ni, Dan Ma, Qin Fang, Yan Zhang, Yanju Li, Yi Huang, Ying Chen, Xiao Chai, Yun Zhan, Yan Li, Qian Kang, Mei Zhao, Min Liu, Fengqi Zhang, Shisi Huang, Shuangshuang Wen, Bo Deng, Jishi Wang

Summary: Venetoclax plus azacitidine and DLI combination therapy showed significant efficacy in treating relapsed AML patients after allo-HSCT, with hematologic system adverse events being the most common, while other system adverse events were relatively fewer and milder, and no serious adverse events were observed.

ANNALS OF HEMATOLOGY (2022)